Related Experiment Video
Updated: Jan 10, 2026
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
Prognostic value of CD49d in CLL: Systematic review and meta-analysis
Piotr Limanówka1, Aleksandra Szczuraszyk1, Paulina Moszyńska1
1Student Research Group of Microbiology and Immunology, Department of Microbiology and Immunology, Medical University of Silesia in Katowice, Jordana 19, Zabrze 41-800, Poland.
Insights
CD49d protein levels accurately predict outcomes in chronic lymphocytic leukemia (CLL). This meta-analysis confirms CD49d
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- CD49d is a protein found on chronic lymphocytic leukemia (CLL) cells.
- Its role in CLL pathogenesis and prognostic significance is under ongoing investigation.
Purpose of the Study:
- To conduct a meta-analysis evaluating the prognostic value of CD49d in CLL.
- To synthesize evidence on CD49d's predictive capability for patient survival and disease progression.
Main Methods:
- Systematic literature search across PubMed, Web of Science, and Embase.
- Meta-analysis of hazard ratios (HR) for overall survival (OS), treatment-free survival (TFS), and progression-free survival (PFS).
- Inclusion of 19 studies with 6457 CLL patients.
Main Results:
- CD49d demonstrated significant predictive value for OS (HR=2.28), TFS (HR=2.06), and PFS (HR=3.63).
- Low to moderate heterogeneity was observed across survival endpoints.
- CD49d reliably distinguished high-risk patients independent of other clinical factors.
Conclusions:
- CD49d is a high-quality prognostic biomarker for CLL clinical outcomes.
- Its ability to predict risk of death, progression, or treatment need is clinically relevant.
- Further research should explore CD49d in novel treatment contexts and bimodal expression patterns.
Abstract:
CD49d is a protein present on CLL cells that have been shown to be involved in pathological processes associated with this hematological malignancy. Although its prognostic significance has been shown before, new studies have emerged since. We performed a meta-analysis of studies aimed at determining the prognostic value of CD49d in CLL. We systematically searched three databases: PubMed, Web of Science, and Embase. Hazard ratios and corresponding confidence intervals for overall survival, treatment-free survival, and progression-free survival were extracted from selected studies and were pooled using random-effects models. Based on our search strategy, we retrieved a total of 562 records, with 19 being included in the final analysis, comprising 6457 patients. Results from meta-analysis showed high predictive value of CD49d in terms of OS, TFS, and PFS with estimated HR values of 2.28, 2.06, and 3.63, respectively. Heterogeneity estimation showed a lack of it in terms of OS, a low degree regarding PFS analysis, and moderate heterogeneity in terms of TFS. Our work provides evidence for the high quality of CD49d as a prognostic factor for clinical outcomes for CLL patients. It is highly suggestive that CD49d is able to distinguish patients with a higher risk of death, progression, or need for treatment without its dependence on other clinical factors, making it highly reliable in a clinical setting. It is necessary to assess its utility in the context of novel treatment options and determine the importance of bimodal expression of CD49d regarding prognostic value.
